研究报告 2025/06 www.leadleo.com 2025年 中国乳腺增生用药行业概览：当"她未言说" 的疼痛被听见，中国女性健康市场是否已 按下"加速键"？ 2025 China Breast Hyperplasia Medication Industry 2025年中国バストアップ薬産業 报告标签：乳腺科、乳腺增生症 主笔人：钟琪 报告提供的任何内容（包括但不限于数据、文字、图表、图像等）均系头豹研究院独有的高度机密性 文件（在报告中另行标明出处者除外）。 ，任何人不得以任何方式擅自 复制、再造、传播、出版、引用、改编、汇编本报告内容，若有违反上述约定的行为发生，头豹研究 院保留采取法律措施、追究相关人员责任的权利。头豹研究院开展的所有商业活动均使用"头豹研究院 "或"头豹"的商号、商标，头豹研究院无任何前述名称之外的其他分支机构，也未授权或聘用其他任何 第三方代表头豹研究院开展商业活动。 研究报告 | 2025/06 中国乳腺增生用药行业 西药方面，治疗乳腺增生症的药物有他莫昔芬 与溴隐亭。他莫昔芬有竞争性抑制体内雌激素 作用，对乳房疼痛有较好的缓解作用，也可改 善中成药起效慢的弊端。中药方面， ...

Group 1: Middle East Geopolitical Risks - The Middle East region has high geopolitical uncertainty, with structural conflicts persisting despite temporary de-escalations[5] - The potential for localized control or conflict in the Strait of Hormuz poses significant risks to global shipping and energy supply[6] - In extreme scenarios, a blockade of the Strait could lead to a supply gap of approximately 12.7% of global oil demand[6] Group 2: Impact on Global Supply Chains - If conflicts escalate, oil and chemical transport through the Strait of Hormuz could decrease by 25% compared to pre-conflict levels[6] - Asian economies, particularly China, India, Japan, and South Korea, face the highest exposure to risks from Middle Eastern energy supplies[7] - The chemical industry will be directly impacted, with disruptions likely to affect downstream sectors such as transportation, pharmaceuticals, and electronics[8] Group 3: China's Response and Strategies - China must diversify its import sources for products heavily reliant on Middle Eastern supplies, particularly in energy and chemicals[8] - Key products at risk include liquefied propane and butane (50.5% reliance), crude oil and asphalt (48.2%), and various chemical compounds (42.4%)[8] - The report suggests enhancing domestic production capabilities and exploring alternative import channels from countries like Canada, Algeria, and Brazil[73]

Group 1: Product Overview - The company produces over 50 types of medicines, with more than 100 specifications, of which over 30 are pediatric drugs, covering the highest proportion of respiratory, digestive, anti-allergy, antibiotic, and nutritional supplements for children [1] - Pediatric drugs account for approximately 70% of the company's product mix, while adult drugs, including gynecological products, make up about 30% [1] Group 2: Market Potential - China's medical expenditure is expected to grow significantly, driven by increasing health awareness and a large base of approximately 250 million children aged 0-14, despite a declining birth rate [2] - The demand for pediatric medicines is stable, supported by parents' increasing focus on children's health, with certain segments like ADHD showing rising demand [2] Group 3: R&D Focus - The company has over 30 years of experience in pediatric drug R&D, continuously innovating in taste, dosage forms, and packaging to enhance competitiveness [2] - Future R&D will focus on pediatric medications, emphasizing dosage form innovation and expanding the pediatric population for existing drugs [4][5] Group 4: Sales Strategy - The company plans to enhance its sales channels, including increasing online sales and participating in national medical insurance negotiations [6] - The company is exploring acquisition opportunities primarily in the children's health sector, focusing on technology complementarity and channel synergy [7]

仙琚制药(002332.SZ)公告称，公司于近日收到国家药品监督管理局下发的噻托溴铵吸入喷雾剂境内生 产药品注册受理通知书。噻托溴铵吸入喷雾剂规格为每瓶60喷，每喷递送剂量为噻托溴铵2.5μg，药液 浓度含噻托溴铵0.2262mg/ml。该品种境内生产药品注册工作进入了审评阶段，如顺利通过审批将丰富 公司的产品线，有利于提升公司的市场竞争力。但药品注册审批工作流程有一定时间周期，存在不确定 性因素，敬请广大投资者审慎决策，注意投资风险。 ...

中国经济网北京7月10日讯 今日，同宇新材（301630）在深交所上市。 同宇新材本次发行募集资金总额为84,000.00万元，募集资金净额为76,037.83万元，拟用于江西同宇新材 料有限公司年产20万吨电子树脂项目（一期）和补充流动资金。 本次发行前，张驰任公司董事长、总经理，直接持有公司1,199.73万股股份，占公司股份总数的 39.99%，同时，张驰为四会兆宇唯一普通合伙人并通过四会兆宇间接控制公司5.26%的表决权。张驰控 制的公司表决权比例合计为45.25%，为公司的控股股东。 张驰和苏世国于2021年12月9日签署了《一致行动协议》，双方确认，自公司2015年12月23日成立至 今，双方作为直接或间接通过第三方持有公司股权的股东，对公司生产经营及其他重大事务决定在事实 上保持一致，对行使公司的股东权利从而依法决定或影响公司的生产经营及其他重大事务在事实上保持 一致，双方作为公司的经营管理决策者的，对公司的生产经营及其他重大事务的依法决定或执行在事实 上保持一致。基于上述事实，自公司成立至今，双方存在事实上一致行动关系。同时，双方约定自协议 签署之日起在公司日常生产经营及其他重大事宜决策等诸方 ...

Company Overview - Tongyu New Materials has been deeply engaged in the electronic resin field for nearly 10 years, breaking the monopoly of international leading companies in the lead-free and halogen-free copper-clad laminate applicable electronic resin sector [2] - The company specializes in the research, production, and sales of electronic resins, primarily used in the production of copper-clad laminates, with products including MDI modified epoxy resin, DOPO modified epoxy resin, high-bromine epoxy resin, BPA-type phenolic epoxy resin, and phosphorus-containing phenolic resin curing agents [2] Industry Insights - The electronic resin industry is crucial as it is one of the three main raw materials for producing copper-clad laminates, which are fundamental materials for processing printed circuit boards (PCBs) [2] - The copper-clad laminate industry in mainland China has seen rapid growth, with the output value increasing from $6.1 billion in 2014 to $9.3 billion in 2023, benefiting from the global PCB industry shifting to mainland China [2] Financial Performance - The company achieved operating revenues of 1.193 billion yuan, 886 million yuan, and 952 million yuan for the years 2022, 2023, and 2024, with year-on-year growth rates of 25.95%, -25.70%, and 7.47% respectively [2] - The net profit attributable to the parent company for the same years was 188 million yuan, 164 million yuan, and 143 million yuan, with year-on-year growth rates of 38.98%, -12.51%, and -12.87% respectively [2] - In Q1 2025, the company reported operating revenue of 276 million yuan, a year-on-year increase of 25.60%, while the net profit attributable to the parent company was 33 million yuan, a decrease of 4.43% year-on-year [2] IPO Details - The company plans to issue 10 million new shares in its IPO, raising 840 million yuan, with the funds intended for a 200,000-ton electronic resin project and to supplement working capital [3] - The company is currently experiencing tight production capacity, with utilization rates exceeding 100% during the reporting period [3] Valuation and Market Performance - Tongyu New Materials has a certain valuation advantage, with an issuance price-to-earnings ratio of 23.7 times, compared to an average dynamic P/E ratio of 36.88 times for comparable companies [5] - If the company achieves the average valuation of comparable companies on its first trading day, it would require a 55.6% increase from its issuance price [5] - The issuance price of 84 yuan is relatively high, and similar new stocks with prices around this level have shown an average first-day increase of 85.36%, significantly lower than the average first-day increase of 291.59% for new stocks over the past year [5]

Investment Rating - The report maintains a rating of "Accumulate" for the company [4] Core Views - The company has achieved continuous revenue and profit growth for five consecutive years, demonstrating strong operational resilience and sustainable business model [2][3] - The acquisition of Yingu Pharmaceutical allows the company to enter the high-barrier nasal spray market, with significant growth potential anticipated from the core product, phenylquinhydramine nasal spray [2] - The company is expected to benefit from the aging population in China, leading to an expansion in the orthopedic medication market [8] Financial Performance Summary - Revenue is projected to grow from 3,311 million yuan in 2023 to 5,111 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 10.6% [1] - Net profit attributable to the parent company is expected to increase from 568 million yuan in 2023 to 1,099 million yuan in 2027, reflecting a CAGR of about 13.0% [1] - The company’s return on equity (ROE) is forecasted to remain strong, increasing from 20.3% in 2023 to 24.4% in 2027 [1] Growth Drivers - The company is focusing on channel expansion and differentiation to enhance loyalty and resource allocation in retail pharmacies [3] - The product matrix is diverse, with significant growth potential in core products, particularly in second-tier regions and grassroots medical institutions [3] - The company is embracing digitalization and AI to improve operational efficiency across various functions [3] Market Position - The company is recognized as a leading player in the domestic traditional Chinese medicine patch market, with a well-established brand and extensive product line [8] - The report highlights the company's ability to maintain a competitive edge through effective marketing integration and focus on core products [8]

Core Insights - Tolremo Therapeutics is a Swiss biotech company founded in 2017, focusing on the development of CBP/p300 bromodomain inhibitors to combat non-genetic cancer drug resistance [2][4][6] - The company has identified a key mechanism governing transcriptional resistance pathways and developed an oral small molecule inhibitor, TT125-802, which targets CBP/p300 [6][8] - Tolremo has completed a $39 million Series A financing round to accelerate the clinical development of TT125-802, which has shown promising preclinical efficacy in combination with targeted therapies for specific advanced tumors [9] Company Overview - Tolremo Therapeutics is a spin-off from ETH Zurich, founded by Stefanie Flückiger-Mangual, who serves as the CEO [2] - The company aims to reverse non-genetic drug resistance in cancer through targeted transcriptional reprogramming [4][7] Product Development - TT125-802 is designed to block the interaction between CBP/p300 and DNA, preventing early transcriptional escape mechanisms in cancer cells [8] - The inhibitor has demonstrated significant clinical activity in preclinical models of non-small cell lung cancer, colorectal cancer, and prostate cancer when used in combination with existing targeted therapies [8] Clinical Trials and Milestones - In November 2023, Tolremo announced the completion of its first human clinical trial for TT125-802, marking a significant milestone in its development [8] - The company plans to continue clinical trials to evaluate the efficacy of TT125-802 in combination with targeted therapies for specific advanced tumors, including those with EGFR and KRAS mutations [9] Recognition and Innovation - Tolremo Therapeutics was listed in the 2024 TOP100 Swiss Startups, highlighting its status as one of the most innovative and promising companies in Switzerland [11]

Core Viewpoint - The announcement indicates that the subsidiary Aitemei (Suzhou) Pharmaceutical Technology Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of Tiotropium Bromide Inhalation Powder for the treatment of Chronic Obstructive Pulmonary Disease (COPD) [1] Group 1 - Aitemei has been granted a Clinical Trial Approval Notice for Tiotropium Bromide Inhalation Powder, which is intended for use in COPD [1] - The projected domestic sales for Tiotropium Bromide Inhalation Powder are 555 million yuan in 2022, 522 million yuan in 2023, and 493 million yuan in 2024 [1] - The drug must undergo clinical trials and receive further approval before it can be manufactured and marketed, indicating that there will be no significant short-term impact on the company's operations [1]

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]